HIV-1 inhibitor-15 (compound 9d) is a potent and broad-spectrum inhibitor targeting HIV-1. It exhibits inhibitory activity against HIV-1 WT, L100I, K103N, Y181C, and E138K with respective EC50 values of 1.7 nM, 4 nM, 2 nM, 6 nM, and 9 nM. In addition to its high efficacy, HIV-1 inhibitor-15 possesses favorable solubility, safety profiles, and oral bioavailability [1].
HIV-1 inhibitor-35 (compound 74) is a highly potent inhibitor of the HIV-1 virus, exhibiting EC50 values of 80 nM and 70 nM for LTR and CMV, respectively, in HEK293 cells. Additionally, HIV-1 inhibitor-35 demonstrates inhibitory activity against HepG2 liver cancer cells, with a CC50 value of 40 nM. Moreover, HIV-1 inhibitor-35 shows promise as a potential HIV-1 latency reversing agent [1].